Circulation, Vol 62, 449-461, Copyright © 1980 by American Heart Association
In the Persantine-Aspirin Reinfarction Study (PARIS) trial, 2026 persons
who had recovered from myocardial infarction (MI) were randomized into
three groups: Persantine plus aspirin (PR/A) (n = 810); aspirin alone (ASA)
(n = 810); placebo (PLBO) (n = 406). The average length of follow-up study
was 41 months. Results for the three specified primary end points were:
total mortality 16% lower in PR/A and 18% lower in ASA compared with PLBO;
coronary mortality 24% and 21% lower; incidence of nonfatal MI plus fatal
coronary disease 25% and 24% lower. These differences were not satistically
significant by the study criterion (Z greater than or equal to 2.6). By
life-table analysis, the rates of coronary mortality and coronary incidence
were about 50% lower in the PR/A group than in the PLBO group from 8-24
months, and for coronary incidence all Z values were greater than or equal
to 2.6; ASA rates were about 30% lower than PLBO rates, and for coronary
incidence, Z values were greater than or equal to 2.6 at two points. For
these end points, from 8-20 months, PR/A rates were about 30% lower than
ASA rates, but all Z values were less than 2.0 PR/A and ASA patients
entering within 6 months of last MI showed the largest percentage
reductions in mortality; only the difference between PR/A and PLBO groups
for 3-year coronary mortality yielded a Z value of 2.6.
ARTICLES
Persantine and aspirin in coronary heart disease. The Persantine- Aspirin Reinfarction Study Research Group
This article has been cited by other articles:
 |
|
 |
|
  T. A. Nahra, K. L. Reiter, R. A. Hirth, J. E. Shermer, and J. R. C. Wheeler Cost-Effectiveness of Hospital Pay-for-Performance Incentives Med Care Res Rev, February 1, 2006; 63(1_suppl): 49S - 72S. [Abstract] [PDF]
|
|
|
|
 |
|
 H. M. Krumholz, Y.-T. Chen, and M. J. Radford Aspirin and the Treatment of Heart Failure in the Elderly Arch Intern Med, February 26, 2001; 161(4): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade Antithrombotic Agents in Coronary Artery Disease Chest, January 1, 2001; 119(1_suppl): 228S - 252S. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Albers Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients? Neurology, March 14, 2000; 54(5): 1022 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, J. L. Halperin, R. McBride, O. Benavente, M. Man-Son-Hing, and R. A. Kronmal Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events: Meta-analysis and Hypotheses Arch Neurol, March 1, 2000; 57(3): 326 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nabuchi, Q. H. Li, and Z. L. Zhu Total Occlusion of Left Main Coronary Artery Trunk in a Young Man Asian Cardiovasc Thorac Ann, December 1, 1999; 7(4): 313 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Figueredo, I. Diamond, H.-Z. Zhou, and S. A. Camacho Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H2091 - H2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Wilterdink and J. D. Easton Dipyridamole Plus Aspirin in Cerebrovascular Disease Arch Neurol, September 1, 1999; 56(9): 1087 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Gorelick, G. V. R. Born, R. B. D'Agostino, D. F. Hanley Jr, L. Moye, and C. J. Pepine Therapeutic Benefit : Aspirin Revisited in Light of the Introduction of Clopidogrel Stroke, August 1, 1999; 30(8): 1716 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]
|
|
|
|
 |
|
 E. J. Weiss, P. F. Bray, M. Tayback, S. P. Schulman, T. S. Kickler, L. C. Becker, J. L. Weiss, G. Gerstenblith, and P. J. Goldschmidt-Clermont A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis N. Engl. J. Med., April 25, 1996; 334(17): 1090 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weil, D. Colin-Jones, M. Langman, D. Lawson, R. Logan, M. Murphy, M. Rawlins, M. Vessey, and P. Wainwright Prophylactic aspirin and risk of peptic ulcer bleeding BMJ, April 1, 1995; 310(6983): 827 - 830. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Hasselblad and D. C. McCrory Meta-analytic Tools for Medical Decision Making: A Practical Guide Med Decis Making, February 1, 1995; 15(1): 81 - 96. [Abstract] [PDF]
|
|
|
|
|
|
C. Patrono Aspirin as an Antiplatelet Drug N. Engl. J. Med., May 5, 1994; 330(18): 1287 - 1294. [Full Text]
|
|
|
|
|
|
Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|